动物造模,透明细胞肾癌裸鼠模型 z-bio 2021-08-16 1054

　　Objective: To use patient-derived clear cell renal carcinoma (ccRCC) cells (patient-derived cells, PDC) to establish a patient-derived tumor xenograft model (PDX model), to detect the sensitivity of ccRCCPDC to molecularly targeted drugs, and to clinically Perform diagnosis and treatment.

　　Methods ccRCCPDC was subcutaneously inoculated into nude mice, and the molecular target drugs sunitinib, sorafenib, lenvatinib, regorafenib, and apatinib were administered orally And Anlotinib. The inhibitory effect of the drug on the subcutaneous tumorigenesis of ccRCCPDC in nude mice. Collect cell and tumor tissue samples, use quantitative PCR technology to detect molecular targeted drug targets (VEGFR and other receptor tyrosine protein kinases and other protein kinases belonging to the ERK, AKT and MAPK signaling pathways), and determine the genetic background of ccRCCPDC experiment. Is it stable?

　　Results We successfully obtained 5 ccRCCPDCs, and inoculated nude mice with the above ccRCCPDCs to obtain a nude mouse subcutaneous tumor model of kidney cancer. In the process of culturing PDC cells in vitro, we expressed molecular targeted drug targets. .., reduction or loss. However, the expression of molecular-targeted drug targets in tumor tissues is relatively stable, and the proliferation of tumor-induced PDC cells in nude mice is caused; the inhibitory effect of molecular-targeted drugs on the subcutaneous tumorigenic effect of ccRCCPDC in nude mice is patient-derived. There are obvious individual differences. Among the selected targeted drugs, lenvatinib has stronger anti-tumor activity than some other targeted drugs.

　　Conclusion This study can use patient-derived renal clear cell carcinoma cell lines to establish a kidney cancer animal model, which provides theoretical and experimental basis for related clinical diagnosis and treatment. Drug cells.